Literature DB >> 12651630

Switch moiety in agonist/antagonist dual effect of S19 ribosomal protein dimer on leukocyte chemotactic C5a receptor.

Arjun Shrestha1, Megumi Shiokawa, Takumasa Nishimura, Hiroshi Nishiura, Yuji Tanaka, Norikazu Nishino, Yoko Shibuya, Tetsuro Yamamoto.   

Abstract

The cross-linked homodimer of S19 ribosomal protein (RP S19) induces monocyte predominant infiltration due to a dual effect on the C5a receptor in leukocyte chemotaxis, agonistic to monocytes and antagonistic to polymorphonuclear leukocytes (PMN) (H. Nishiura, Y. Shibuya, T. Yamamoto, Lab Invest 1998, 78:1615-1623). The agonistic ligand moiety was recently determined to be -Leu131-Asp132-Arg133- (Y. Shibuya et al, Am J Pathol 2001, 159:2293-2301). In this study we determined the moiety responsible for the antagonistic function. A C-terminal analogue peptide of RP S19, with 18 residues containing the agonistic ligand moiety as a part, reproduced the dual function in the leukocyte chemotaxis. A C5a analogue peptide attracted PMN as well as monocytes. When C-terminal 12 residues of RP S19 after the agonistic moiety, IAGQVAAANKKH, were connected to the C5a peptide, the chimeric peptide newly obtained the dual function, indicating that the C-terminal portion of RP S19 functions as a converter from the agonist to the antagonist. C-terminal truncation analyses indicated that the C-terminal His was not essential but the next Lys was necessary for the converter function. The homodimer of a mutant RP S19 that was truncated for the C-terminal 4 residues lost the monocyte selectivity in the leukocyte infiltration in vivo as in the case of the leukocyte chemotaxis in vitro. These results indicated that the conversion of the RP S19 dimer from agonist to antagonist of C5a receptor is attributed to the IAGQVAAANKK moiety between Ile134 and Lys144.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651630      PMCID: PMC1851224          DOI: 10.1016/S0002-9440(10)63934-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  18 in total

1.  A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides.

Authors:  J M Prober; G L Trainor; R J Dam; F W Hobbs; C W Robertson; R J Zagursky; A J Cocuzza; M A Jensen; K Baumeister
Journal:  Science       Date:  1987-10-16       Impact factor: 47.728

2.  Novel function of C4a anaphylatoxin. Release from monocytes of protein which inhibits monocyte chemotaxis.

Authors:  T Tsuruta; T Yamamoto; S Matsubara; S Nagasawa; S Tanase; J Tanaka; K Takagi; T Kambara
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

3.  A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration.

Authors:  W Falk; R H Goodwin; E J Leonard
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

4.  Identification of receptor-binding sites of monocyte chemotactic S19 ribosomal protein dimer.

Authors:  Y Shibuya; M Shiokawa; H Nishiura; T Nishimura; N Nishino; H Okabe; K Takagi; T Yamamoto
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

5.  Apoptotic cells of an epithelial cell line, AsPC-1, release monocyte chemotactic S19 ribosomal protein dimer.

Authors:  T Nishimura; K Horino; H Nishiura; Y Shibuya; T Hiraoka; S Tanase; T Yamamoto
Journal:  J Biochem       Date:  2001-03       Impact factor: 3.387

6.  Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells.

Authors:  F Boulay; L Mery; M Tardif; L Brouchon; P Vignais
Journal:  Biochemistry       Date:  1991-03-26       Impact factor: 3.162

7.  Complement C4-derived monocyte-directed chemotaxis-inhibitory factor. A molecular mechanism to cause polymorphonuclear leukocyte-predominant infiltration in rheumatoid arthritis synovial cavities.

Authors:  S Matsubara; T Yamamoto; T Tsuruta; K Takagi; T Kambara
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

8.  The chemotactic receptor for human C5a anaphylatoxin.

Authors:  N P Gerard; C Gerard
Journal:  Nature       Date:  1991-02-14       Impact factor: 49.962

9.  Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors.

Authors:  S J Siciliano; T E Rollins; J DeMartino; Z Konteatis; L Malkowitz; G Van Riper; S Bondy; H Rosen; M S Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

10.  Monocyte chemotactic factor in rheumatoid arthritis synovial tissue. Probably a cross-linked derivative of S19 ribosomal protein.

Authors:  H Nishiura; Y Shibuya; S Matsubara; S Tanase; T Kambara; T Yamamoto
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

View more
  5 in total

Review 1.  Do not let death do us part: 'find-me' signals in communication between dying cells and the phagocytes.

Authors:  C B Medina; K S Ravichandran
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

2.  Monocyte chemotactic S19 ribosomal protein dimer in atherosclerotic vascular lesion.

Authors:  Lei Shi; Shigeyuki Tsurusaki; Noriko Futa; Tamami Sakamoto; Tomoko Matsuda; Norikazu Nishino; Ryuji Kunitomo; Michio Kawasuji; Kazutaka Tokita; Tetsuro Yamamoto
Journal:  Virchows Arch       Date:  2005-10-19       Impact factor: 4.064

3.  Pro- and anti-apoptotic dual functions of the C5a receptor: involvement of regulator of G protein signaling 3 and extracellular signal-regulated kinase.

Authors:  Hiroshi Nishiura; Hideo Nonaka; Ivette S Revollo; Umeko Semba; Ying Li; Yoshihiko Ota; Atsushi Irie; Kumiko Harada; John H Kehrl; Tetsuro Yamamoto
Journal:  Lab Invest       Date:  2009-03-30       Impact factor: 5.662

4.  RP S19 C-terminal peptide trimer acts as a C5a receptor antagonist.

Authors:  Hiroshi Nishiura; Toru Kawakami; Mutsuki Kawabe; Nahoko Kato-Kogoe; Naoko Yamada; Keiji Nakasho; Koji Yamanegi
Journal:  Biochem Biophys Rep       Date:  2016-05-10

Review 5.  Immune Aging and How It Works for Inflammation and Fibrosis.

Authors:  Hiroshi Nishiura; Mai Imasaka; Koji Yamanegi; Jiro Fujimoto; Masaki Ohmuraya
Journal:  Front Physiol       Date:  2022-01-04       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.